Cost reduction of viral vector processes using 3D nanofiber-based cell culture systems in upstream bioprocessing

Tuesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Cost reduction of viral vector processes using 3D nanofiber-based cell culture systems in upstream bioprocessing

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

Across viral vector manufacturing process, novel technologies are being investigated to both directly decrease costs of goods and indirectly reduce costs by increasing yield and productivity. In this webinar, a disruptive upstream nanotechnology that vastly increases yield (3x) over traditional processes will be introduced.

Attendees will learn how novel nanofiber-based cell culture systems can provide up to 70% cost reduction per gene therapy dose produced. Sustainable cellulose nanofibers interact with cells to form 3D cell dense spheroids, providing up to 60x higher surface area compared to bead-based microcarriers. These systems also remove the need for enzymes in seed train and cell passaging, providing cost savings in material, labor, and waste, and reduce the time needed in seed train.

Data including a process economy model for large scale production of a gene therapy and a comparison between nanofiber products and traditional bead-based microcarriers will be presented. Greater than 90% transfection efficiencies and 3x higher viral vector titer yields are achieved as a result of the larger surface area and homogenous spheroids of nanofibers.

Discover a novel single-use sustainable cellulose nanofiber microcarrier that allows for 60x surface area versus traditional microcarriers
See data showing that Cellevat3d® nanofibers offer up to 3x higher yields than traditional microcarriers and >90% transfection efficiency
Find out why using nanofiber microcarriers provides up to 70% cost reduction in the production of one dose of a gene therapy

Rob Noel

Commercialisation Consultant at 55Biomarkets

Rob has 20 years developing, implementing and commercialising biomanufacturing technologies within a wide range of GMP-based operations. He has experience of food products, plasma proteins, biologics, ADCs and vaccines, working as project lead/director within major suppliers, new technology companies and CDMOs. In the last 5 years he has focussed on strategic marketing of tech, value proposition analysis, and investment with VLP, pDNA & gene and cell therapy markets.

Geddy Hamblen

Application Manager, North America at Cellevate

Geddy has over a decade in upstream bioprocess experience, working across the industry. Geddy previously worked at Mirus Bio and Sartorius, supporting the reagents and upstream process equipment in cell and gene therapy. On an industry side, Geddy was previously director of an industrial microbiology startup, overseeing process development, scale up, and tech transfer of industrial fermentation. Geddy has also worked in upstream process development and manufacturing for plasmid production and CHO processes. Geddy’s academic background includes using AAV and lentivirus to develop viral vaccines for animal health.

Geddy has a master’s degree in biotechnology from Texas A&M University.

Christel Fenge

Chief Technology Officer at Cellevate

Christel Fenge is a globally experienced corporate leader with an over 30 years track record in product development, management and marketing in the biopharma industry. Christel held positions as VP R&D Bioprocess at Cytiva, VP Marketing and Product Management Fermentation Technologies at Sartorius, as General Manager of Recipharm Biologics, a mid-sized CMO and senior management positions in biopharmaceutical development at AstraZeneca. She started her industrial career in cell culture process development at Pharmacia & Upjohn involved in the development of RefactoÒ. Christel received her doctorate in Biochemistry from the University of Hanover, Germany. She now works as an independent techno-commercial advisor and part time CTO for Cellevate.